Paris-based Sanofi (SNY) announced yesterday that it was terminating its option and license agreement with Fremont, Calif.-based Ardelyx (ARDX) for its NaP2b inhibitors. The termination will go into effect Sept. […]
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2015-09-02 05:41:002015-09-02 13:02:00Sanofi Terminates a $200 Million NaP2b Development Deal With Ardelyx
